Follow
Alberto Ocana
Alberto Ocana
Unit Head. Experimental Therapeutics. Hospital Clínico San Carlos. Madrid. Director Translational
Verified email at sescam.jccm.es - Homepage
Title
Cited by
Cited by
Year
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ...
Journal of the National Cancer Institute 106 (6), dju124, 2014
28472014
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...
Journal of the National Cancer Institute 99 (8), 628-638, 2007
10232007
Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ...
Cancer epidemiology, biomarkers & prevention 23 (7), 1204-1212, 2014
7742014
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis
E Amir, B Seruga, S Niraula, L Carlsson, A Ocaña
Journal of the National Cancer Institute 103 (17), 1299-1309, 2011
6752011
High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
A Bruna, RS Darken, F Rojo, A Ocaña, S Peñuelas, A Arias, R Paris, ...
Cancer cell 11 (2), 147-160, 2007
5792007
Neutrophils in cancer: prognostic role and therapeutic strategies
A Ocana, C Nieto-Jiménez, A Pandiella, AJ Templeton
Molecular cancer 16, 1-7, 2017
3952017
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2014
3922014
Drug resistance in metastatic castration-resistant prostate cancer
B Seruga, A Ocana, IF Tannock
Nature reviews Clinical oncology 8 (1), 12-23, 2011
3922011
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors
JC Montero, S Seoane, A Ocaña, A Pandiella
Clinical cancer research 17 (17), 5546-5552, 2011
3072011
Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu, IF Tannock
Nature reviews Clinical oncology 8 (4), 200-209, 2011
3062011
HER3 overexpression and survival in solid tumors: a meta-analysis
A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir
JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2013
2312013
Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis
S Niraula, A Ocana, M Ennis, PJ Goodwin
Breast cancer research and treatment 134, 769-781, 2012
2192012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs
S Niraula, B Seruga, A Ocana, T Shao, R Goldstein, IF Tannock, E Amir
Journal of Clinical Oncology 30 (24), 3012-3019, 2012
2032012
Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ...
European urology 67 (4), 740-749, 2015
2022015
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis
A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ...
PloS one 9 (4), e95219, 2014
1752014
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis
H Goldvaser, TA Barnes, B Šeruga, DW Cescon, A Ocaña, D Ribnikar, ...
JNCI: Journal of the National Cancer Institute 110 (1), 31-39, 2018
1632018
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
M Yu, A Ocana, IF Tannock
Cancer and Metastasis Reviews 32, 211-227, 2013
1622013
Resistance to antibody–drug conjugates
S Garcia-Alonso, A Ocana, A Pandiella
Cancer research 78 (9), 2159-2165, 2018
1562018
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
FE Vera-Badillo, R Shapiro, A Ocana, E Amir, IF Tannock
Annals of Oncology 24 (5), 1238-1244, 2013
1522013
When are “positive” clinical trials in oncology truly positive?
A Ocana, IF Tannock
Journal of the National Cancer Institute 103 (1), 16-20, 2011
1452011
The system can't perform the operation now. Try again later.
Articles 1–20